Half-year report · HY
4544.TEDINET S100X1GC
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥124.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥243.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥120.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥2.3bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥956m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥305m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥4.7bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | −¥187m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥205m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥821m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥142m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥821m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥274.0bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥279.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥291.4bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥138.9bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥142.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥135.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥137.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥136.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥39.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥40.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥39.6bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥40.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥47.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥22.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥16.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥3.61 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.6 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.47 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥3.61 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 49.2% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥2.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥2.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥2.7bn |
| Clinical Lab Testing Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥79.4bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥79.2bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥249m |
| Clinical Lab Testing Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥930m |
| In Vitro Diagnostics Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥31.4bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥29.4bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥4.8bn |
| Sterilization And Related Servicesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥15.9bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥15.8bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥90m |
| Sterilization And Related Servicesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥126.7bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥124.4bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.3bn |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥5.1bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥2.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥2.5bn |
| Clinical Lab Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥76.7bn |
| Clinical Lab Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥76.5bn |
| Clinical Lab Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥205m |
| Clinical Lab Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2.9bn |
| In Vitro Diagnostics Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥31.2bn |
| In Vitro Diagnostics Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥29.0bn |
| In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.2bn |
| In Vitro Diagnostics Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Sterilization And Related Servicesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥14.5bn |
| Sterilization And Related Servicesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥14.4bn |
| Sterilization And Related Servicesreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9m |
| Sterilization And Related Servicesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥879m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥122.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥120.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 3288600 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.0575 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 3269300 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0571 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 2312100 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0404 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 2104600 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0368 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 1849200 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0323 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 1571300 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0275 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 1538600 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0269 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 1298500 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0227 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 1272200 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0222 | |
| Number of shares held | InterimInstant | 27870700 | |
| Shareholding ratio | InterimInstant | 0.4871 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 263000 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 57102000 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 571020 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 114022 | |
| Number of shares issued shares voting rights | InterimInstant | 57479022 | |
| Number of voting rights issued shares voting rights | InterimInstant | 571020 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 263000 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 263000 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0046 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 263000 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 263000 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0046 | |
| Cash and deposits | Prior1YearInstant | 40885000000 | JPY |
| Cash and deposits | InterimInstant | 39564000000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 46619000000 | JPY |
| Notes and accounts receivable trade and contract assets | InterimInstant | 47878000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 5580000000 | JPY |
| Merchandise and finished goods | InterimInstant | 6460000000 | JPY |
| Work in process | Prior1YearInstant | 8509000000 | JPY |
| Work in process | InterimInstant | 9406000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 7183000000 | JPY |
| Raw materials and supplies | InterimInstant | 7130000000 | JPY |
| Other ca | Prior1YearInstant | 11228000000 | JPY |
| Other ca | InterimInstant | 8623000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |